These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 12205067)

  • 21. In vitro activities of gemifloxacin (SB 265805, LB20304) against recent clinical isolates of Chlamydia pneumoniae.
    Roblin PM; Reznik T; Kutlin A; Hammerschlag MR
    Antimicrob Agents Chemother; 1999 Nov; 43(11):2806-7. PubMed ID: 10543770
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.
    Roblin PM; Reznik T; Kutlin A; Hammerschlag MR
    Antimicrob Agents Chemother; 2003 Mar; 47(3):1135-6. PubMed ID: 12604555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The in-vitro activity of OPC-17116, a new 5-methyl substituted quinolone.
    Wise R; Andrews JM; Brenwald N
    J Antimicrob Chemother; 1993 Apr; 31(4):497-504. PubMed ID: 8390433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The in-vitro activity of a new highly active quinolone, DU-6859a.
    Jolley A; Andrews JM; Brenwald N; Wise R
    J Antimicrob Chemother; 1993 Nov; 32(5):757-63. PubMed ID: 8125840
    [No Abstract]   [Full Text] [Related]  

  • 25.
    Kohlhoff S; Huerta N; Hammerschlag MR
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31160287
    [No Abstract]   [Full Text] [Related]  

  • 26. In-vitro activity of roxithromycin against Chlamydia trachomatis.
    Moroni A; Sambri V; Rumpianesi F; Donati M; Cevenini R
    J Chemother; 1991 Jan; 3 Suppl 1():28-9. PubMed ID: 12041779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of Chlamydial infections: 2014 update.
    Kohlhoff SA; Hammerschlag MR
    Expert Opin Pharmacother; 2015 Feb; 16(2):205-12. PubMed ID: 25579069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activity of trovafloxacin against Chlamydia pneumoniae.
    Roblin PM; Kutlin A; Hammerschlag MR
    Antimicrob Agents Chemother; 1997 Sep; 41(9):2033-4. PubMed ID: 9303410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro susceptibility of Chlamydia pecorum to macrolides, tetracyclines, quinolones and beta-lactam.
    Pudjiatmoko ; Fukushi H; Ochiai Y; Yamaguchi T; Hirai K
    Microbiol Immunol; 1998; 42(1):61-3. PubMed ID: 9525782
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibitory activities of quinolones against DNA gyrase of Chlamydia pneumoniae.
    Ameyama S; Shinmura Y; Takahata M
    Antimicrob Agents Chemother; 2003 Jul; 47(7):2327-9. PubMed ID: 12821490
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity of lomefloxacin (SC 47111 or NY-198) against Chlamydia trachomatis strains.
    Segreti J; Kessler HA; Kapell K; Trenholme GM
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):87S-88S. PubMed ID: 2791503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro susceptibility of Mycoplasma hominis clinical isolates to tetracyclines, quinolones and macrolides.
    Samra Z; Rosenberg S; Soffer Y
    Diagn Microbiol Infect Dis; 2002 Dec; 44(4):359-61. PubMed ID: 12543541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How useful is the Chlamydia micro-immunofluorescence (MIF) test for the gynaecologist?
    Wagenvoort JH; Koumans D; van de Cruijs M
    Eur J Obstet Gynecol Reprod Biol; 1999 May; 84(1):13-5. PubMed ID: 10413220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development potential of rifalazil and other benzoxazinorifamycins.
    Rothstein DM; Shalish C; Murphy CK; Sternlicht A; Campbell LA
    Expert Opin Investig Drugs; 2006 Jun; 15(6):603-23. PubMed ID: 16732714
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The in-vitro antibiotic susceptibility of Chlamydia pneumoniae.
    Fenelon LE; Mumtaz G; Ridgway GL
    J Antimicrob Chemother; 1990 Dec; 26(6):763-7. PubMed ID: 2081718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determination of the inhibitory concentration 50% (IC50) of four selected drugs (chlortetracycline, doxycycline, enrofloxacin and difloxacin) that reduce in vitro the multiplication of Chlamydophila psittaci.
    Failing K; Theis P; Kaleta EF
    Dtsch Tierarztl Wochenschr; 2006 Nov; 113(11):412-7. PubMed ID: 17147151
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activity of azithromycin (CP-62,993) against Chlamydia trachomatis and Chlamydia pneumoniae.
    Agacfidan A; Moncada J; Schachter J
    Antimicrob Agents Chemother; 1993 Sep; 37(9):1746-8. PubMed ID: 8239579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PCR detection and differentiation of Chlamydia pneumoniae, Chlamydia psittaci and Chlamydia trachomatis.
    Rasmussen SJ; Douglas FP; Timms P
    Mol Cell Probes; 1992 Oct; 6(5):389-94. PubMed ID: 1361961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The activity of ciprofloxacin and other 4-quinolones against Chlamydia trachomatis and Mycoplasmas in vitro.
    Ridgway GL; Mumtaz G; Gabriel FG; Oriel JD
    Eur J Clin Microbiol; 1984 Aug; 3(4):344-6. PubMed ID: 6237903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The in vitro activity of BMS-284756, a new des-fluorinated quinolone.
    Weller TM; Andrews JM; Jevons G; Wise R
    J Antimicrob Chemother; 2002 Jan; 49(1):177-84. PubMed ID: 11751785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.